Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Treated as an insurer. None of the usual models had enough data, so this uses Analyst consensus, Net asset value, and Sales comps instead.
ACCE opinionLemonade Inc. Common Stock (LMND)
Fair value
Not available
ACCE price target
$50.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Price used: $44.92 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus, Net asset value, and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
36
out of 100
Analysts
27% buy
11 covering
1-year return
-12.6%
Dividend yield
0.00%
Lemonade Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Lemonade sells homeowners, renters, pet and car insurance through a mobile-first app, with its own underwriting, claims handling and a reinsurance layer behind it. The structural pitch is the cost base: the company runs on a largely automated, AI-driven claims process and a flat distribution model, which is why gross margin sits at 51.7% for a carrier. Revenue growth of 79.4% is the number that matters most right now, as the book expands across more states and product lines while the company works toward operating profitability (operating margin is still -11.8%, and ROE is -27.0%). The debate is whether that growth can turn into underwriting profit at scale, and the score of 36/100 reflects that the profitability case has not yet been proven. It is worth a deeper look if you want exposure to a high-growth insurtech whose loss ratio trajectory is the central question, and it is not a name where the current financials support a conventional valuation.